Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination ophthalmic formulation containing sodium hyaluronate (also known as hyaluronic acid) and hydrocortisone sodium phosphate. Sodium hyaluronate is a naturally occurring glycosaminoglycan with viscoelastic and lubricating properties, commonly used to hydrate and protect the ocular surface. Hydrocortisone sodium phosphate is a synthetic glucocorticoid corticosteroid that exerts anti-inflammatory effects by suppressing inflammatory cytokines and immune cell activity. The combination aims to synergize the moisturizing effect of hyaluronic acid with the mild anti-inflammatory action of low-dose hydrocortisone, providing relief for dry eye disease (DED) by improving tear film stability, reducing para-inflammation on the ocular surface, and alleviating symptoms associated with meibomian gland dysfunction[1][3]. Clinical studies have shown this combination improves both objective signs (tear film stability) and subjective symptoms in DED patients[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + hydrocortisone sodium phosphate.